

PUBLIC DISCLOSURE OF DISPOSITION OF ANTI-DOPING MATTER UNDER RULE 14.3.2 - CHIJINDU UJAH (GBR)

1. On 6 August 2021, Chijindu Ujah¹ (“the **Athlete**”) provided a Sample In-Competition during the Tokyo 2020 Olympic Games, which resulted in an Adverse Analytical Finding for Ostarine and S-23² (“the **AAF**”) which are Non-Specified substances, prohibited at all times.
2. On 12 August 2021, the International Testing Agency (“**ITA**”) (acting on behalf of the International Olympic Committee) notified the Athlete and the AIU of the AAF in accordance with Article 7.2.3 of the IOC ADR and informed the Athlete of the potential Consequences of the AAF and disciplinary procedures under the IOC Anti-Doping Rules applicable to the Games of the XXXII Olympiad Tokyo 2020 (as of March 2021) (“the **IOC ADR**”).
3. On 12 August 2021, the AIU also issued the Athlete with a Notice of Provisional Suspension and Public Disclosure based on the AAF pursuant to the World Athletics Anti-Doping Rules (“**ADR**”) and informed the Athlete, *inter alia*, that the AAF was being brought forward as an apparent Anti-Doping Rule Violation under Article 2.1 and/or Article 2.2 of the IOC ADR by the ITA, which was responsible (in accordance with Article 7.1.1 of the IOC ADR) for determining, on behalf of the IOC (i) whether an Anti-Doping Rule Violation had been committed and (ii) the applicable Consequences related to the Olympic Games.
4. The AIU also informed the Athlete that the determination of (further) Consequences beyond the Olympic Games to be imposed pursuant to the ADR would be referred to the AIU on behalf of World Athletics (if applicable) following the conclusion of the disciplinary procedures under the IOC ADR.
5. On 18 February 2022, the CAS Anti-Doping-Division (“**CAS ADD**”) provided World Athletics with a copy of the Award issued by a Sole Arbitrator of the CAS ADD in relation to the AAF (“the **CAS Award**”). The CAS Award ruled that:
 - 5.1. the Athlete had committed an Anti-Doping Rule Violation pursuant to Article 2.1 of the IOC ADR;
 - 5.2. the Athlete’s results in the Men’s 100m event on 31 July and 1 August 2021 and in the Men’s 4x100m relay final on 6 August 2021 were disqualified, together with the forfeiture of any medals, diplomas, points and prizes, in accordance with Article 10.1 of the IOC ADR; and
 - 5.3. the results of the Great Britain team in the Men’s 4x100m relay final on 6 August 2021 were disqualified, together with the forfeiture of any medals, diplomas, points and prizes, in accordance with Article 11.3 of the IOC ADR.

¹ <https://worldathletics.org/athletes/great-britain-ni/chijindu-ujah-14410429>

² Ostarine and S-23 are Selective Androgen Receptor Modulators (“**SARMS**”). SARMS are Prohibited Substances on the WADA 2021 Prohibited List under the category S1.2 Other Anabolic Agents. They are non-Specified Substances prohibited at all times.

6. Following the expiry of the deadline for appeal against the CAS Award on 11 March 2022, on 17 March 2022, the AIU issued the Athlete with a Notice of Charge in relation to the Consequences to be imposed under the ADR for the Athlete's violation of Article 2.1 of the IOC ADR/Rule 2.1 ADR.
7. The AIU, the Athlete and the World Anti-Doping Agency ("the **Parties**") subsequently entered into a Case Resolution Agreement in accordance with Rule 10.8.2 ADR pursuant to which:
 - 7.1. the Athlete acknowledges that he committed an ADRV under Rule 2.1 of the ADR;
 - 7.2. the Athlete has established that the ADRV was not intentional pursuant to Rule 10.2.1(a) and Rule 10.2.2 as a result of the Athlete's ingestion of a contaminated supplement such that the applicable period of Ineligibility is a period of two (2) years;
 - 7.3. the Athlete has not been able to demonstrate that he is entitled to any reduction in the period of Ineligibility based on his level of Fault for the ADRV pursuant to Rule 10.6.1(b) of the ADR; and
 - 7.4. taking into consideration how promptly the Athlete admitted the ADRV upon notification, the Parties agree that the period of Ineligibility shall (i) be reduced by two (2) months to a total of 22 months and (ii) commence on the date of the ADRV, i.e., **from 6 August 2021 until 5 June 2023.**
8. Following the Case Resolution Agreement, there is no right of appeal in the matter under the ADR and the disposition of the Athlete's case is therefore final and published in accordance with Rule 14.3.2 ADR.

Monaco, 29 September 2022